In the case of unresectable HCC, therapeutic strategies combining anti-VEGF therapy, immunotherapy, and TACE have been proposed owing to advances in systemic therapy, but the timing of TACE and evidence regarding the suspension and resumption of systemic therapy are not standardized. This evidence concerns the gene VEGFA and hepatocellular carcinoma.